Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Agile Therapeutics Equity Warrants AGRX


Primary Symbol: AGXRW

Healthcare
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.


OTCPK:AGXRW - Post by User

Agile Therapeutics Equity Warrants
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(152)
•••
Post by whytestockson Jul 15, 2024 11:02pm
73 Views
Post# 36134058

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV
Just In: $AGRX SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, SPR, UMBF, AGRX on Behalf of Shareholders | BenzingaNEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...AGRX - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, SPR, UMBF, AGRX on Behalf of Shareholders | Benzinga


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities